Anti-cancer blood-vessel treatment for relapsed childhood brain tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a treatment that targets tumor blood-vessel growth to slow or shrink relapsed/progressive brain tumors in children. It may help if standard options are no longer working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child has a relapsed or growing (progressive) brain tumor such as medulloblastoma, ependymoma, or ATRT
- The tumor was confirmed by biopsy or by special tumor testing done at diagnosis or relapse
- Your child is under 20 years old at the time of the original diagnosis
- Blood counts and key organ tests are strong enough to safely start study treatment (liver, kidneys, white blood cells, platelets)
- Your child can safely take the study medicines, and there is no current infection, pregnancy, or breastfeeding
- There are no major exclusions such as uncontrolled heart problems or serious medication allergies
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination treatment for children and young adults with brain tumors that have come back or not responded to standard therapy. The treatment includes a gene therapy (SGT-53) that delivers a normal TP53 gene, a checkpoint inhibitor drug that helps the immune system attack the cancer, and focused radiation. The goal is to see if this combination is safe and can shrink tumors.
This study tests a personalized treatment plan for children and young adults whose medulloblastoma or ependymoma has come back. It aims to guide doctors using new tissue from surgery or biopsy after earlier treatments are fully finished.
This trial tests whether adding a thyroid hormone (liothyronine) to a standard chemotherapy combination (bevacizumab, irinotecan, temozolomide) can help children and young adults with medulloblastoma that has come back after initial treatment.
This trial tests a combination of two oral drugs (axitinib and metronomic etoposide) for children and young adults whose medulloblastoma or ependymoma has come back or is not responding to standard therapy. The goal is to see if this daily pill treatment can control tumor growth with manageable side effects.
This trial tests a combination of chemotherapy drugs (topotecan given into the spine plus maintenance chemo) for children under 6 with high-risk embryonal brain tumors. The goal is to see if this approach can improve outcomes after initial treatment.
This trial tests a new immune therapy using your child's own specially trained white blood cells to fight brain tumors. The treatment is given directly into the fluid around the brain, and it is for children with specific types of brain cancer.
Hear when a new Medulloblastoma Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.